| Literature DB >> 30872684 |
Mark van Dam1,2,3, Jesse Rijks1,3, Elke Dorenbos1,3, Flore Horuz2, Karin van Dael2, Anita Vreugdenhil4,5,6.
Abstract
Obesity causes modifications in the kidneys reversed by weight loss in adults. There is little data on renal function and effects of weight loss in children with obesity. The aim of this prospective study was to examine renal function and effect of a lifestyle intervention in children with overweight, obesity and morbid obesity. Two hundred forty-five children (age 12.4 ± 3.3 years, 40% boys, BMI z-score 3.46 ± 0.70) participating in an out-patient lifestyle intervention were included. Children with at least 12 months follow-up (n = 144 (58.8%)) were included in the longitudinal study. Anthropometry, blood analysis and blood pressure measurements were performed at baseline and follow-up. Glomerular filtration rate (GFR) was estimated using the Schwartz and FAS equation. eGFR was de-indexed using body surface area. Different cut-off points for defining glomerular hyperfiltration were used for stratification. Depending on the definition and equation used, glomerular hyperfiltration was present in 2% to 18% of the participants. After intervention, de-indexed eGFR decreased significantly in children with baseline glomerular hyperfiltration, depending on the eGFR equation and definition for glomerular hyperfiltration used. No associations of changes in eGFR with changes in BMI z-score, blood pressure or parameters of glucose and lipid metabolism were found. In conclusion, after one year of lifestyle intervention, eGFR decreases in hyperfiltrating children and adolescents with overweight, obesity and morbid obesity. eGFR and changes over time in children with obesity depend on eGFR equation used and on de-indexing for body surface area.Entities:
Mesh:
Year: 2019 PMID: 30872684 PMCID: PMC6418201 DOI: 10.1038/s41598-019-40767-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart of study inclusion. Abbreviations: COACH, Centre for Overweight Adolescent and Children’s Healthcare.
Baseline characteristics of the total cohort and stratified according to non-dropout versus dropout after one year lifestyle intervention.
| Variable | Total (n = 245) | Non-dropout (n = 144) | Dropout (n = 101) | |
|---|---|---|---|---|
| Age (years) | 12.4 ± 3.3 | 12.0 ± 3.0 | 13.0 ± 3.5 | 0.025* |
| Boys (%) | 40 | 45 | 34 | 0.09 |
| BMI z-score | 3.46 ± 0.70 | 3.45 ± 0.65 | 3.48 ± 0.78 | 0.76 |
| BSA (m²) | 1.86 ± 0.46 | 1.81 ± 0.42 | 1.93 ± 0.50 | 0.06 |
| Overweight (%) | 14.3 | 11.1 | 18.8 | 0.10 |
| Obese (%) | 42.9 | 48.6 | 34.7 | 0.04* |
| Morbid obese (%) | 42.9 | 40.3 | 46.5 | 0.36 |
| Prepubertal (%) | 30.3 | 28.9 | 31.8 | 0.72 |
| Peripubertal (%) | 20.4 | 26.3 | 13.6 | 0.09 |
| Postpubertal (%) | 49.3 | 44.7 | 54.5 | 0.31 |
| Waist circumference z-score | 5.7 (1.4–13.9) | 5.5 (1.4–13.9) | 5.7 (1.8–11.5) | 0.46 |
| Hip circumference z-score | 4.3 ± 2.0 | 4.3 ± 1.9 | 4.4 ± 2.2 | 0.60 |
| Waist-to-hip ratio | 0.93 ± 0.09 | 0.93 ± 0.07 | 0.93 ± 0.10 | 0.99 |
| Systolic BP z-score | 0.3 ± 1.1 | 0.3 ± 1.0 | 0.3 ± 1.2 | 0.91 |
| Diastolic BP z-score | −0.4 ± 1.2 | −0.4 ± 1.0 | −0.4 ± 1.4 | 0.92 |
| eGFR-Schwartz (ml/min/1.73 m²) | 117.4 ± 20.5 | 119.6 ± 19.9 | 114.3 ± 21.1 | 0.06 |
| eGFR-Schwartz > 135 ml/min/1.73 m² (%) | 18.0 | 22.2 | 12.0 | 0.04* |
| eGFR-Schwartz > 140 ml/min/1.73 m² (%) | 12.7 | 15.3 | 8.9 | 0.17 |
| eGFR-Schwartz > 150 ml/min/1.73 m² (%) | 5.7 | 6.9 | 4.0 | 0.41 |
| eGFR-Schwartz de-indexed (ml/min) | 124.2 ± 30.8 | 123.5 ± 28.0 | 125.2 ± 34.4 | 0.66 |
| Serum creatinine (mg/dL)/Q value | 0.97 ± 0.15 | 0.96 ± 0.14 | 0.98 ± 0.16 | 0.32 |
| eGFR-FAS (ml/min/1.73 m²) | 113.3 ± 17.1 | 113.9 ± 16.3 | 112.3 ± 18.3 | 0.47 |
| eGFR-FAS > 135 ml/min/1.73 m² (%) | 11.4 | 13.0 | 9.9 | 0.68 |
| eGFR-FAS > 140 ml/min/1.73 m² (%) | 6.9 | 6.9 | 6.9 | 0.99 |
| eGFR-FAS > 150 ml/min/1.73 m² (%) | 2.0 | 1.4 | 3.0 | 0.41 |
| eGFR-FAS de-indexed (ml/min) | 121.4 ± 34.6 | 118.9 ± 30.5 | 124.9 ± 39.5 | 0.18 |
| UACR (mg albumin/g creatinine) | 4.4 (0–203.3) | 4.0 (0.0–36.2) | 4.4 (0.0–203.3) | 0.10 |
| Microalbuminuria (%) | 2.9 | 2.1 | 4.0 | 0.45 |
| Fasting glucose (mmol/L) | 4.1 (2.1–5.7) | 4.0 (2.5–5.6) | 4.1 (2.1–5.7) | 0.003* |
| Fasting insulin (pmol/L) | 15.3 (2.0–111.2) | 15.0 (2.0–111.2) | 15.5 (3.0–76.8) | 0.40 |
| HOMA-IR | 2.5 (0.4–19.3) | 2.5 (0.4–19.3) | 2.8 (0.5–18.4) | 0.16 |
| HbA1c (%) | 5.3 ± 0.4 | 5.3 ± 0.4 | 5.3 ± 0.5 | 0.25 |
| Total cholesterol (mmol/L) | 4.5 ± 0.8 | 4.6 ± 0.8 | 4.3 ± 0.9 | 0.03* |
| HDL-cholesterol (mmol/L) | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 | 0.67 |
| LDL-cholesterol (mmol/L) | 2.7 ± 0.7 | 2.8 ± 0.7 | 2.6 ± 0.7 | 0.08 |
| Triacylglycerides (mmol/L) | 1.0 (0.4–3.7) | 1.1 (0.4–3.7) | 1.0 (0.4–3.1) | 0.20 |
Abbreviations: BMI, body mass index; BSA, body surface area; BP, blood pressure; eGFR, estimated glomerular filtration rate; FAS, full age spectrum; UACR, urine albumin-to-creatinine ratio; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein.
Figure 2(A) Correlation between baseline eGFR-Schwartz and eGFR-FAS in ml/min/1.73 m2. Univariate linear regression model: y = 4.97 + 0.99* × with R2 = 0.685. (B) Correlation between baseline de-indexed eGFR-Schwartz and eGFR-FAS in ml/min. Univariate linear regression model: y = 23.74 + 0.83* × with R2 = 0.863.
Comparison of pre- and post-intervention data of the children with at least one year of follow-up (n = 144).
| Variable | Pre | Post | Mean of paired differences (pre-post) | |
|---|---|---|---|---|
| Age (years) | 12.0 ± 3.0 | 13.3 ± 3.0 | −1.3 ± 0.3 | <0.001* |
| BMI z-score | 3.45 ± 0.65 | 3.28 ± 0.74 | 0.17 ± 0.44 | <0.001* |
| BSA (m²) | 1.81 ± 0.42 | 1.92 ± 0.38 | −0.11 ± 0.10 | <0.001* |
| Normal weight (%) | 0.0 | 1.4 | — | 0.50 |
| Overweight (%) | 11.1 | 18.1 | — | 0.052 |
| Obese (%) | 48.6 | 43.8 | — | 0.28 |
| Morbid obese (%) | 40.3 | 36.8 | — | 0.30 |
| Prepubertal (%) | 28.9 | 18.0 | — | 0.06 |
| Peripubertal (%) | 26.3 | 36.9 | — | 0.38 |
| Postpubertal (%) | 44.7 | 45.0 | — | 0.50 |
| Waist circumference z-score | 5.5 (1.4–13.9) | 5.3 (1.2–13.8) | 0.1 (−5.8–4.2) | 0.94 |
| Hip circumference z-score | 4.3 ± 1.9 | 4.4 ± 1.8 | −0.1 ± 0.8 | 0.09 |
| Waist-to-hip ratio | 0.93 ± 0.07 | 0.91 ± 0.08 | 0.02 ± 0.08 | 0.04* |
| Systolic BP z-score | 0.3 ± 1.0 | 0.1 ± 1.2 | 0.2 ± 1.3 | 0.09 |
| Diastolic BP z-score | −0.4 ± 1.0 | −0.7 ± 1.2 | 0.3 ± 1.2 | 0.01* |
| Serum creatinine (mg/dL) | 0.55 ± 0.13 | 0.61 ± 0.13 | −0.06 ± 0.07 | <0.001* |
| eGFR-Schwartz (ml/min/1.73 m²) | 119.6 ± 19.9 | 111.6 ± 18.3 | 8.0 ± 15.0 | <0.001* |
| eGFR-Schwartz > 135 ml/min/1.73 m² (%) | 22.2 | 11.8 | — | 0.004* |
| eGFR-Schwartz > 140 ml/min/1.73 m² (%) | 15.3 | 7.6 | — | 0.03* |
| eGFR-Schwartz > 150 ml/min/1.73 m² (%) | 6.9 | 2.8 | — | 0.15 |
| eGFR-Schwartz de-indexed (ml/min) | 123.5 ± 28.0 | 122.5 ± 25.6 | 0.9 ± 17.6 | 0.53 |
| Serum creatinine (mg/dL)/Q value | 0.96 ± 0.14 | 0.99 ± 0.13 | −0.03 ± 0.12 | 0.003* |
| eGFR-FAS (ml/min/1.73 m²) | 113.9 ± 16.3 | 110.1 ± 15.1 | 3.8 ± 15.1 | 0.003* |
| eGFR-FAS > 135 ml/min/1.73 m² (%) | 13.0 | 5.6 | — | 0.03* |
| eGFR-FAS > 140 ml/min/1.73 m² (%) | 6.9 | 4.2 | — | 0.34 |
| eGFR-FAS > 150 ml/min/1.73 m² (%) | 1.4 | 1.4 | — | 0.99 |
| eGFR-FAS de-indexed (ml/min) | 118.9 ± 30.5 | 122.4 ± 29.6 | −3.5 ± 17.0 | 0.02* |
| UACR (mg albumin/g creatinine) | 4.0 (0.0–36.2) | 3.5 (0.0–401.3) | 0.4 (−21.0–24.4) | 0.86 |
| Microalbuminuria (%) | 2.1 | 4.3 | — | 0.45 |
| Fasting glucose (mmol/L) | 4.0 (2.5–5.6) | 4.2 (2.5–5.3) | −0.2 (−1.3–1.9) | 0.01* |
| Fasting insulin (pmol/L) | 15.0 (2.0–111.2) | 14.7 (2.1–64.8) | 0.4 (−46.3–28.8) | 0.19 |
| HOMA-IR | 2.5 (0.4–19.3) | 2.7 (0.4–13.9) | −0.2 (−9.5–7.3) | 0.03* |
| HbA1c (%) | 5.3 ± 0.4 | 5.2 ± 0.3 | 0.2 ± 0.3 | <0.001* |
| Total cholesterol (mmol/L) | 4.6 ± 0.8 | 4.3 ± 0.8 | 0.3 ± 0.6 | <0.001* |
| HDL-cholesterol (mmol/L) | 1.2 ± 0.3 | 1.2 ± 0.3 | 0.0 ± 0.2 | 0.22 |
| LDL-cholesterol (mmol/L) | 2.8 ± 0.7 | 2.6 ± 0.7 | 0.2 ± 0.6 | <0.001* |
| Triacylglycerides (mmol/L) | 1.1 (0.4–3.7) | 1.0 (0.4–3.8) | 0.1 (−1.9–1.7) | 0.04* |
Abbreviations: BMI, body mass index; BSA, body surface area; BP, blood pressure; eGFR, estimated glomerular filtration rate; FAS, full age spectrum; UACR, urine albumin-to-creatinine ratio; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein.
Comparison of pre- and post-intervention eGFR-Schwartz stratified according to baseline glomerular hyperfiltration per definition.
| Definition of glomerular hyperfiltration (n, percentile of 144 participants) | Pre eGFR-Schwartz (ml/min) | Post eGFR-Schwartz (ml/min) | Mean of paired differences (pre-post) | 95% confidence interval | |
|---|---|---|---|---|---|
| eGFR-Schwartz > 135 ml/min/1.73 m² (n = 32, 22.2%) | 139.0 ± 32.1 | 128.1 ± 30.5 | 10.8 ± 20.6 | 3.4–18.3 | 0.006* |
| eGFR-Schwartz > 140 ml/min/1.73 m² (n = 22, 15.3%) | 138.1 ± 32.0 | 128.8 ± 33.9 | 9.3 ± 15.4 | 2.5–16.1 | 0.010* |
| eGFR-Schwartz > 150 ml/min/1.73 m² (n = 10, 6.9%) | 154.3 ± 28.4 | 140.9 ± 30.2 | 13.4 ± 14.6 | 3.0–23.8 | 0.017* |
| eGFR-FAS > 135 ml/min/1.73 m² (n = 18, 12.5%) | 142.7 ± 29.2 | 129.3 ± 31.7 | 13.3 ± 15.8 | 5.5–21.2 | 0.002* |
| eGFR-FAS > 140 ml/min/1.73 m² (n = 10, 6.9%) | 153.5 ± 29.4 | 142.6 ± 31.5 | 10.9 ± 19.2 | −2.8–24.6 | 0.105 |
| eGFR-FAS > 150 ml/min/1.73 m² (n = 2, 1.4%) | 141.1 ± 8.9 | 126.9 ± 33.2 | 14.2 ± 24.3 | n/a | n/a |
Abbreviations: eGFR, estimated glomerular filtration rate; n/a, not applicable.
Comparison of pre- and post-intervention eGFR-FAS stratified according to baseline glomerular hyperfiltration per definition.
| Definition of glomerular hyperfiltration (n, percentile of 144 participants) | Pre eGFR-FAS (ml/min) | Post eGFR-FAS (ml/min) | Mean of paired differences (pre-post) | 95% confidence interval | |
|---|---|---|---|---|---|
| eGFR-Schwartz > 135 ml/min/1.73 m² (n = 32, 22.2%) | 127.1 ± 31.0 | 119.2 ± 29.0 | 7.9 ± 16.9 | 1.8–14.0 | 0.013* |
| eGFR-Schwartz > 140 ml/min/1.73 m² (n = 22, 15.3%) | 123.6 ± 28.3 | 117.2 ± 30.9 | 6.5 ± 13.4 | 0.5–12.4 | 0.035* |
| eGFR-Schwartz > 150 ml/min/1.73 m² (n = 10, 6.9%) | 135.6 ± 24.1 | 126.3 ± 26.9 | 9.3 ± 14.8 | −1.3–19.8 | 0.079 |
| eGFR-FAS > 135 ml/min/1.73 m² (n = 18, 12.5%) | 136.8 ± 30.6 | 126.0 ± 34.9 | 10.7 ± 16.1 | 2.8–18.7 | 0.011* |
| eGFR-FAS > 140 ml/min/1.73 m² (n = 10, 6.9%) | 148.5 ± 32.6 | 140.5 ± 37.7 | 8.0 ± 19.6 | −6.0–22.0 | 0.227 |
| eGFR-FAS > 150 ml/min/1.73 m² (n = 2, 1.4%) | 130.7 ± 9.1 | 116.5 ± 31.6 | 14.2 ± 22.5 | n/a | n/a |
Abbreviations: eGFR, estimated glomerular filtration rate; n/a, not applicable.